Peripheral Nerve, NMJ & Muscle Antibodies

Antibody testing in peripheral neurology spans three compartments: the neuromuscular junction (NMJ), the peripheral nerve, and the muscle. This page is the lab-side companion to the clinical Neuromuscular chapter — it covers what to order, what assay, what sample, what the titer means, and how the result changes management. Clinical syndrome detail (MG phenotypes, GBS variants, myositis presentations) is intentionally left for the clinical chapters; here, the focus is on the assay and its decision impact.

🔹 Bottom Line: Peripheral Nerve, NMJ & Muscle Antibodies

  • NMJ: AChR binding first; if negative, MuSK and LRP4. MuSK-positive → rituximab is highly effective (IgG4 mechanism). CT chest at diagnosis (thymoma in 10–15% AChR+). Striational antibodies raise thymoma suspicion. Anti-VGCC + SOX1 = LEMS / SCLC.
  • Peripheral nerve: Anti-GM1 = MMN → IVIG; avoid steroids/PLEX (worsen). Anti-MAG (DADS) = rituximab + check SPEP/IFE. Anti-GQ1b = Miller Fisher. Paranodal (NF155, CNTN1, CASPR1) = “refractory CIDP” → rituximab.
  • Muscle (myositis): order a myositis-specific panel — TIF1γ + cancer surveillance, MDA5 + interstitial lung disease, HMGCR + statin discontinuation + IVIG, Jo-1 + anti-synthetase syndrome workup, cN-1A + IBM.
  • Methodology: cell-based assay (CBA) is gold standard for cell-surface NMJ targets; older VGKC-complex testing is obsolete on its own. Myositis testing uses immunoprecipitation + line blot — order as a panel, single antibodies miss the picture.
  • Send before treatment when possible — steroids/IVIG can transiently lower titers and cause false negatives.

1. Neuromuscular Junction (NMJ) Antibodies

Order in suspected myasthenia gravis (MG) and related NMJ disorders. The order matters: AChR binding antibody first, then add MuSK and LRP4 if negative. Striational antibodies are a thymoma marker. Anti-VGCC + SOX1 flags LEMS / SCLC.

Anti-Acetylcholine Receptor (AChR) Antibodies

  • Three sub-tests: binding (first-line; positive in ~85% of generalized MG, ~50% of ocular MG), blocking (occasionally positive when binding is negative), modulating (highest sensitivity but less specific).
  • Sample: serum. Sensitivity does not improve with CSF.
  • Methodology: radioimmunoassay (classic); some labs use cell-based assays for low-affinity AChR detection in patients otherwise labeled seronegative.
  • Titer: correlates loosely with severity at the individual level but cannot replace clinical assessment.
  • Treatment impact: AChR+ patients are candidates for eculizumab/ravulizumab (anti-C5) and efgartigimod/rozanolixizumab (FcRn antagonists) when refractory. CT chest mandatory at diagnosis — thymoma in 10–15%; thymectomy is standard for AChR+ generalized MG <65 years.
  • Repeat testing: 6–12 months later if initially negative and clinical suspicion remains — some patients seroconvert.

Anti-MuSK Antibodies

  • Sample: serum.
  • Methodology: cell-based assay; older ELISA acceptable but CBA has higher sensitivity.
  • Isotype: predominantly IgG4 — does NOT activate complement (different mechanism from AChR).
  • Treatment impact: rituximab is dramatically effective (IgG4 antibodies arise from short-lived plasmablasts → B-cell depletion eliminates them). Pyridostigmine often poorly tolerated. Thymectomy NOT recommended. Rozanolixizumab is FDA-approved for MuSK-MG; eculizumab is NOT (complement-independent mechanism).

Anti-LRP4 Antibodies

  • Sample: serum.
  • Methodology: cell-based assay.
  • Yield: positive in ~15–20% of double-seronegative (AChR-/MuSK-) MG. Order after AChR and MuSK are negative.
  • Treatment impact: variable response; standard MG immunotherapy ladder applies.

Striational Antibodies

  • Targets: titin, ryanodine receptor, voltage-gated K+ channel — intracellular striated-muscle proteins.
  • Sample: serum.
  • Significance: not pathogenic — a marker. Strongly associated with thymoma, especially in young patients with MG.
  • Treatment impact: positivity reinforces thymoma screening urgency — repeat CT chest if initial imaging is negative and striational antibodies remain positive.

Anti-VGCC (P/Q-type) Antibodies — LEMS Marker

  • Target: presynaptic voltage-gated calcium channel.
  • Sample: serum.
  • Methodology: radioimmunoassay.
  • Cancer association: SCLC in ~60%. Anti-SOX1 (AGNA) is often co-positive and supports paraneoplastic etiology.
  • Treatment impact: positive result → tumor workup (CT chest, FDG-PET if negative) and amifampridine (3,4-DAP) FDA-approved for symptomatic treatment. Tumor treatment + immunotherapy for paraneoplastic cases.

Anti-Ganglionic AChR (α3) Antibodies

  • Target: ganglionic acetylcholine receptor α3 subunit at autonomic ganglia (distinct from neuromuscular AChR).
  • Sample: serum.
  • Indication: subacute pandysautonomia (orthostatic hypotension + GI dysmotility + fixed dilated pupils + anhidrosis + neurogenic bladder).
  • Treatment impact: positive → consider IVIG / plasmapheresis / immunosuppression for autoimmune autonomic ganglionopathy.

VGKC-Complex Antibody — Obsolete

  • “VGKC-complex” positive without LGI1 or CASPR2 specificity is now considered uninterpretable. Do not treat based on this result alone; reflex to LGI1 / CASPR2 cell-based assays — if negative, the original VGKC-complex result is non-specific noise.

NMJ Antibody Order Algorithm

  1. Clinical suspicion of MG → anti-AChR binding antibody.
  2. If positive → CT chest (thymoma). Consider adding striational antibodies in young patients.
  3. If negative → add MuSK, then LRP4. If all negative → consider repeat testing in 6–12 months, electrodiagnostic confirmation (RNS, SFEMG).
  4. For LEMS phenotype (proximal weakness, hyporeflexia improving with exercise) → anti-VGCC + SOX1. If positive → SCLC workup.
  5. For pandysautonomia → ganglionic AChR (α3).

🔹 Clinical Relevance: Serotyping Drives MG Therapy

MG treatment is now antibody-specific. AChR-positive refractory disease is the indication for complement inhibitors (eculizumab, ravulizumab) and FcRn antagonists (efgartigimod, rozanolixizumab). MuSK-positive disease is the indication for rituximab — and a contraindication to thymectomy. Don’t escalate empirically; serotype first.

2. Peripheral Nerve Antibodies

Pattern recognition on the clinical and EMG side narrows the differential; antibody testing then confirms the syndrome and (crucially) changes the choice of immunotherapy. Pick the antibody based on the syndrome, not vice-versa.

Anti-MAG IgM — DADS Neuropathy

  • Target: myelin-associated glycoprotein.
  • Sample: serum.
  • Methodology: ELISA (Mayo and most reference labs).
  • Indication: chronic distal-acquired demyelinating symmetric (DADS) neuropathy with sensory ataxia + tremor.
  • Always check SPEP / immunofixation — anti-MAG is nearly always associated with an IgM kappa monoclonal gammopathy (MGUS or Waldenström). Refer to hematology if M-protein is found.
  • Treatment impact: rituximab is the cornerstone. IVIG, plasmapheresis, and steroids have limited benefit; standard CIDP therapy fails.

Anti-GM1 IgM — Multifocal Motor Neuropathy (MMN)

  • Target: GM1 ganglioside on motor axons.
  • Sample: serum.
  • Methodology: ELISA.
  • Indication: asymmetric distal motor weakness without sensory involvement, conduction block on EMG — mimics ALS.
  • Treatment impact: IVIG is the cornerstone (chronic regimen). Steroids and plasmapheresis can WORSEN MMN — avoid.

Anti-GQ1b IgG — Miller Fisher Syndrome & Variants

  • Target: GQ1b ganglioside on ocular motor nerves and primary sensory afferents.
  • Sample: serum.
  • Methodology: ELISA.
  • Sensitivity: positive in ~85% of Miller Fisher (ophthalmoplegia + ataxia + areflexia); also positive in Bickerstaff brainstem encephalitis and some pharyngeal-cervical-brachial GBS variants.
  • Treatment impact: positive supports GBS-spectrum diagnosis; treatment (IVIG or PLEX) is the same regardless of antibody status. Mainly useful for atypical / variant presentations.

Other GBS Spectrum Antibodies

  • Anti-GD1a: AMAN / AMSAN (especially post-Campylobacter).
  • Anti-GT1a: pharyngeal-cervical-brachial variant.
  • Practical note: GBS spectrum antibodies are not necessary for diagnosis in typical presentations. Useful in: atypical features, variant identification, research / prognosis.

Anti-Sulfatide IgM

  • Target: sulfatide on myelin.
  • Sample: serum.
  • Indication: chronic predominantly sensory neuropathy; often co-positive with anti-MAG; usually associated with M-protein.
  • Treatment impact: similar to anti-MAG approach (rituximab in selected cases).

Paranodal Antibodies — Autoimmune Nodopathies

  • Targets: paranodal proteins at the node of Ranvier — neurofascin-155 (NF155), contactin-1 (CNTN1), CASPR1.
  • Sample: serum (some labs offer CSF reflex; serum is primary).
  • Methodology: cell-based assay; older indirect immunofluorescence less reliable.
  • Indication: “refractory CIDP” patients — especially with severe sensory ataxia + tremor (NF155), aggressive distal weakness ± membranous nephropathy (CNTN1), or severe neuropathic pain (CASPR1). Now formally a distinct category in the 2021 EAN/PNS CIDP guideline.
  • Treatment impact: standard CIDP therapies (IVIG, steroids, PLEX) often fail. Rituximab is dramatically effective — order the panel before escalating standard CIDP therapy in refractory cases.

Peripheral Nerve Antibody Order Algorithm

  • Asymmetric distal motor weakness + conduction block → anti-GM1 (test for MMN).
  • Chronic sensory ataxic neuropathy + DADS pattern → anti-MAG + SPEP/IFE.
  • Acute ophthalmoplegia + ataxia ± areflexia → anti-GQ1b (Miller Fisher).
  • Refractory or atypical “CIDP” → paranodal panel (NF155, CNTN1, CASPR1).
  • Painful sensory neuropathy with M-protein → anti-sulfatide.
  • Typical CIDP is usually seronegative — don’t order antibodies routinely.

3. Muscle (Myositis) Antibodies

Myositis-specific antibodies (MSAs) and myositis-associated antibodies (MAAs) define biologically distinct subtypes of inflammatory myopathy that map to different cancer risks, organ involvement, and treatment paths. Order as a panel (immunoprecipitation + line blot is the modern methodology) — single antibodies miss the picture.

Sample & Methodology

  • Sample: serum.
  • Methodology: immunoprecipitation (gold standard, available at reference labs) and/or line blot / dot blot panels.
  • Order strategy: a comprehensive myositis panel (MSA + MAA) — single Jo-1 testing in isolation misses the broader anti-synthetase syndrome and dermatomyositis-specific antibodies.

Dermatomyositis-Specific Antibodies (DM-MSAs)

Antibody Phenotype association Cancer risk Treatment implication
Anti-Mi-2 Classic adult DM with prominent skin findings (“good” DM) Low Generally good response to immunotherapy; lower cancer surveillance burden
Anti-TIF1γ Adult DM (paraneoplastic in >50% in adults >40) HIGH — cancer in >50% of adults >40; juvenile DM ↔ no cancer link Aggressive age-appropriate cancer screening (CT C/A/P, mammography, colonoscopy, PET if negative; repeat × 2 years)
Anti-NXP2 Adult DM with calcinosis; juvenile DM Moderate (adults) Cancer screening in adults; immunotherapy for myositis
Anti-MDA5 Clinically amyopathic DM with rapidly progressive interstitial lung disease (RP-ILD) ± skin ulcers Low Aggressive triple immunotherapy (high-dose steroids + tacrolimus + cyclophosphamide ± rituximab); RP-ILD is the killer
Anti-SAE DM with severe skin disease, dysphagia Possible cancer association Cancer screening; immunotherapy for myositis

Anti-Synthetase Syndrome (Aminoacyl-tRNA Synthetases)

Antibody tRNA synthetase target Notes
Anti-Jo-1 Histidyl-tRNA Most common (~20% of myositis). Classic syndrome: myositis + ILD + arthritis + mechanic’s hands + Raynaud + fever.
Anti-PL-7 Threonyl-tRNA Same syndrome; often more ILD-predominant.
Anti-PL-12 Alanyl-tRNA Often ILD without myositis.
Anti-EJ, OJ, KS, Zo, Ha Other tRNA synthetases Rare; same syndrome spectrum.
  • Treatment impact: positive → HRCT chest + PFTs (DLCO) for ILD; immunotherapy = steroids ± mycophenolate / azathioprine / rituximab. ILD often drives prognosis more than the myositis itself.

Necrotizing Myopathy Antibodies

Antibody Trigger / association Treatment impact
Anti-HMGCR Statin-associated immune-mediated necrotizing myopathy (IMNM). Can persist after statin withdrawal. Stop the statin permanently. IVIG is first-line; add steroids ± mycophenolate / rituximab. Statins should NOT be re-challenged.
Anti-SRP Aggressive necrotizing myopathy without statin trigger. Severe weakness, very high CK. Combination immunotherapy (steroids + IVIG + rituximab); often refractory.

Inclusion Body Myositis

  • Anti-cN-1A (cytosolic 5′-nucleotidase 1A, NT5C1A): supportive of IBM diagnosis (positive in ~30–60%); also seen in Sjögren and SLE.
  • Sample: serum.
  • Treatment impact: confirms biological correlate of clinical/pathologic IBM diagnosis — IBM is treatment-refractory to immunotherapy; cN-1A positivity supports the diagnosis but does NOT change the (limited) treatment approach. Physical therapy + supportive management.

Myositis-Associated Antibodies (MAAs) — Overlap Syndromes

  • Anti-Ro52 (TRIM21): most common MAA; co-positive with many MSAs, especially anti-synthetase. Associated with more severe ILD when co-positive.
  • Anti-PM/Scl: myositis + scleroderma overlap; calcinosis, ILD.
  • Anti-U1-RNP: mixed connective tissue disease (MCTD).
  • Anti-Ku: myositis + scleroderma overlap.

Muscle Antibody Order Algorithm

  1. Suspected inflammatory myopathy → comprehensive myositis panel (MSA + MAA) by immunoprecipitation/line blot.
  2. Anti-TIF1γ+ in adult → urgent age-appropriate cancer surveillance.
  3. Anti-MDA5+ → urgent HRCT chest + PFTs; assume RP-ILD until proven otherwise.
  4. Any anti-synthetase positive → ILD workup (HRCT + PFTs).
  5. Anti-HMGCR+ → discontinue statin; start IVIG-based IMNM regimen.
  6. Anti-cN-1A+ in slow-progressive proximal + distal weakness → supports IBM, set expectations re: immunotherapy.

🔹 Clinical Relevance: Myositis Antibodies Define Subtype + Risk + Therapy

The “inflammatory myopathies” are not one disease but several biologically distinct subtypes. The antibody profile reorders the entire workup: TIF1γ → cancer hunt; MDA5 → ICU-level ILD vigilance; HMGCR → permanent statin discontinuation + IVIG; cN-1A → manage expectations for IBM; Jo-1/PL-7/PL-12 → anti-synthetase workup with ILD/PFTs. Order the full panel before committing to treatment.

Pitfalls and Pearls

  • NMJ: AChR binding first; if negative add MuSK + LRP4 before declaring seronegative. CT chest at MG diagnosis (thymoma). Striational antibodies reinforce thymoma suspicion. MuSK+ → rituximab + no thymectomy. VGCC + SOX1 → SCLC.
  • “VGKC-complex” without LGI1/CASPR2 specificity is uninterpretable — do not treat based on it.
  • Avoid in MG: aminoglycosides, fluoroquinolones, β-blockers, magnesium, neuromuscular blockers — can precipitate crisis.
  • MMN (anti-GM1): IVIG works; steroids and PLEX worsen it.
  • Anti-MAG (DADS): always check SPEP/IFE for M-protein; rituximab is the cornerstone.
  • Paranodal antibodies (NF155, CNTN1, CASPR1): order in any refractory CIDP — rituximab is dramatically effective.
  • Typical CIDP is usually seronegative — don’t order antibodies routinely.
  • Myositis panel order strategy: full MSA+MAA panel by immunoprecipitation; single Jo-1 misses the broader spectrum.
  • TIF1γ in adult myositis: cancer in >50% if >40 years — aggressive surveillance.
  • MDA5: rapidly progressive ILD is the killer — urgent HRCT + PFTs + triple immunotherapy.
  • HMGCR: statin-associated IMNM; stop statin permanently, IVIG first-line, do not rechallenge.
  • cN-1A: supports IBM diagnosis but does not change treatment (IBM is refractory to immunotherapy).
  • Ro52 co-positivity: more severe ILD when paired with anti-synthetase antibodies.
  • Send before immunotherapy when possible — steroids/IVIG/PLEX can transiently lower titers.
  • Cell-based assays for cell-surface NMJ targets; immunoprecipitation / line blot for myositis panels; ELISA for ganglioside / MAG antibodies.

References

  1. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122.
  2. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN). Lancet Neurol. 2017;16(12):976-986.
  3. Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). Lancet Neurol. 2021;20(7):526-536.
  4. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of CIDP. J Peripher Nerv Syst. 2021;26(3):242-268.
  5. Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13(9):533-547.
  6. Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58.
  7. Mammen AL, Allenbach Y, Stenzel W, et al. 239th ENMC International Workshop: Classification of dermatomyositis. Neuromuscul Disord. 2020;30(1):70-92.
  8. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99.
  9. Mayo Clinic Laboratories. Myositis-specific and myositis-associated antibody panel (MYSP / MYSE) — phenotype-specific ordering.